Latest Ratios: P/E Ratio 79.3x · EV/EBITDA 28.1x · ROE 10.8%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $13.3B | $8.2B | $3.3B | — | — | — | — | — |
| Enterprise Value | $16.1B | $11.0B | $6.1B | — | — | — | — | — |
| P/E Ratio → | 79.29 | 43.05 | — | — | — | — | — | — |
| P/S Ratio | 1.03 | 0.64 | 0.29 | — | — | — | — | — |
| P/B Ratio | 8.04 | 4.36 | 1.99 | — | — | — | — | — |
| P/FCF | 33.76 | 20.85 | — | — | — | — | — | — |
| P/OCF | 27.18 | 16.79 | 138.25 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.85 | 0.54 | — | — | — | — | — |
| EV / EBITDA | 28.09 | 19.19 | 14.92 | — | — | — | — | — |
| EV / EBIT | 39.40 | 26.92 | 31.66 | — | — | — | — | — |
| EV / FCF | — | 27.83 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 11.8% | 11.8% | 14.1% | 16.2% | 17.5% | 18.6% | 18.8% | 18.4% |
| Operating Margin | 3.2% | 3.2% | 1.8% | 1.7% | 2.4% | 3.5% | 3.0% | 1.4% |
| Net Profit Margin | 1.5% | 1.5% | -0.2% | -1.8% | -0.7% | 0.7% | 0.4% | -1.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | 10.8% | 10.8% | -1.6% | -22.1% | -6.8% | 6.5% | 2.9% | -10.2% |
| ROA | 3.1% | 3.1% | -0.3% | -2.8% | -1.0% | 1.0% | 0.5% | -1.9% |
| ROIC | 6.7% | 6.7% | 3.5% | 2.5% | 3.1% | 4.4% | 3.8% | 1.5% |
| ROCE | 9.0% | 9.0% | 4.7% | 3.3% | 4.1% | 5.6% | 4.7% | 2.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.51 | 1.51 | 1.76 | 5.99 | 4.69 | 4.71 | 4.04 | 3.44 |
| Debt / EBITDA | 4.97 | 4.97 | 7.07 | 10.50 | 9.39 | 8.70 | 8.58 | 11.20 |
| Net Debt / Equity | — | 1.46 | 1.72 | 5.97 | 4.67 | 4.65 | 3.69 | 3.41 |
| Net Debt / EBITDA | 4.81 | 4.81 | 6.92 | 10.46 | 9.35 | 8.59 | 7.82 | 11.12 |
| Debt / FCF | — | 6.98 | — | 26.65 | — | 17.66 | 15.89 | 40.63 |
| Interest Coverage | 2.59 | 2.59 | 0.85 | 0.45 | 0.80 | 1.42 | 1.19 | 0.38 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.57 | 1.57 | 1.33 | 1.17 | 1.44 | 1.32 | 1.74 | 1.40 |
| Quick Ratio | 1.12 | 1.12 | 0.88 | 0.84 | 0.98 | 0.99 | 1.33 | 1.08 |
| Cash Ratio | 0.05 | 0.05 | 0.04 | 0.01 | 0.01 | 0.05 | 0.35 | 0.03 |
| Asset Turnover | — | 2.01 | 1.90 | 1.60 | 1.42 | 1.21 | 1.23 | 1.19 |
| Inventory Turnover | 13.98 | 13.98 | 15.11 | 18.35 | 14.79 | 18.21 | 15.10 | 18.60 |
| Days Sales Outstanding | — | 27.98 | 37.23 | 41.80 | 41.05 | 43.87 | 45.84 | 50.19 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.3% | 2.3% | — | — | — | — | — | — |
| FCF Yield | 3.0% | 4.8% | — | — | — | — | — | — |
| Buyback Yield | 0.3% | 0.5% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.3% | 0.5% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $220M | $193M | $171M | $171M | $171M | $171M | $171M |
Clinical labor wage inflation
Based on current market data, BTSG trades at a forward P/E of 40.83, which suggests investors are pricing in significant future earnings expansion relative to the broader healthcare services sector and the company's own historical performance as a private-equity-backed entity.
The elevated P/E multiple indicates that the market is placing a high premium on the company's ability to scale its integrated pharmacy and provider model. Investors should monitor whether this valuation is supported by sustained margin expansion, as the current multiple appears to leave little room for earnings misses or regulatory headwinds.
As reported in recent financial statements, the company's ROIC has struggled to gain momentum, hovering at 3.0% in 2026Q1, which suggests that the firm is currently failing to generate returns that meaningfully exceed its cost of capital.
The low ROIC reflects the heavy burden of intangible assets and goodwill from past acquisitions, which continue to dilute the efficiency of invested capital. Until management can demonstrate an ability to drive higher returns from its existing asset base, the company may struggle to justify its current valuation to long-term institutional investors.
According to quarterly filings, the cash conversion cycle has compressed to 13 days in 2026Q1 from a peak of 31 days in 2023Q4, indicating a notable improvement in the company's ability to manage its receivables and inventory turnover.
This reduction in the cash conversion cycle suggests that the company is becoming more effective at collecting payments from government payers and managing its pharmacy inventory. Continued efficiency in this area is critical, as it directly impacts the firm's liquidity and reduces the need for external financing to fund daily operations.
Based on the provided balance sheet data, the debt-to-equity ratio has improved dramatically to 0.13 in 2026Q1, a significant shift from the 5.99 level observed in 2023Q4, which suggests a much more stable foundation for future operations.
The rapid reduction in leverage significantly lowers the company's interest expense burden and mitigates the risk of covenant breaches that often plague PE-backed roll-ups. This improved balance sheet position provides management with greater flexibility to pursue organic growth initiatives rather than focusing solely on debt service.
The P/E ratio is frequently misapplied to this business model because it fails to account for the significant non-cash amortization charges resulting from the PharMerica acquisition, which artificially suppress GAAP net income and distort the company's true earnings power.
Investors should instead focus on Adjusted EBITDA or cash-flow-based metrics to better understand the underlying operational performance of the business. Relying on P/E in this context may lead to an overly pessimistic view of the company's valuation, as it ignores the cash-generative nature of the pharmacy and provider segments.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BTSG stock.
BrightSpring Health Services, Inc. Common Stock's current P/E ratio is 79.3x. The historical average is 43.0x. This places it at the 100th percentile of its historical range.
BrightSpring Health Services, Inc. Common Stock's current EV/EBITDA is 28.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.1x.
BrightSpring Health Services, Inc. Common Stock's return on equity (ROE) is 10.8%. The historical average is -2.9%.
Based on historical data, BrightSpring Health Services, Inc. Common Stock is trading at a P/E of 79.3x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
BrightSpring Health Services, Inc. Common Stock has 11.8% gross margin and 3.2% operating margin.
BrightSpring Health Services, Inc. Common Stock's Debt/EBITDA ratio is 5.0x, indicating high leverage. A ratio above 4x may signal elevated financial risk.